Skip to NavigationSkip to content

Business Services

Daiichi Sankyo name current COO Sunao Manabe as firm's new CEO

Published on: 12/04/19

Daiichi Sankyo have said Sunao Manabe, the company’s current COO will take over from George Nakayama as the firm’s new Chief Executive Officer (CEO).

Manabe, who joined Sankyo Co in 1978, has, since joining the firm, taken on roles of increasing seniority. The company veteran took on the position of President and COO in 2017.

The move from COO to CEO is a familiar pattern in Japanese firms mirrored in Takeda’s appointment of Frenchman Christophe Weber in 2014.

GW Pharma announce Darren Cline as company's new Chief Commercial Officer

Published on: 12/04/19

GW Pharmaceuticals have announced the appointment of Darren Cline as the company’s new US Chief Commercial Officer. Cline will lead the commercialisation of cannabidiol (CBD) based epilepsy medication Epidiolex in the United States.

Cline will succeed Julian Gangolli who announced he would be stepping down from his current role as President of GW Pharma’s US subsidiary, Greenwich Biosciences, in November 2018.

Cline is expected to start in his new role on 22 April 2019. Cline will however work with Gangolli for several weeks as he transitions into the organisation.

Top Ten most popular articles on this week!

This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile Britain’s cost effectiveness body NICE turned down Astellas’ Xtandi in prostate cancer.

Nevertheless our top story looked at Gilead’s announcement they would be laying off one fifth of their workforce. The news came as shares in Indivior plummeted by as much as 70% amid fraud allegations.

Living with a rare chromosome disorder

Published on 11/04/19 at 12:28pm

Rebecca Pender’s daughter Hannah lives with the ultra-rare condition Inv Dup Del 8p, a genetic arrangement that affects just 80 people worldwide. She recounts the struggle to secure a diagnosis, and how the experience shaped her attitude on how we confront rare disease.

Can you shed some light on the nature of Inv Dup Del 8p?

Kymab announces Merck exec Simon Sturge as new CEO

Published on: 08/04/19

UK-based biotech Kymab has identified Merck KGaA executive Simon Sturge as its new Chief Executive Officer, taking over the reins from current CEO and Cambridge Antibody Technology co-founder David Chiswell effective 1 May.

The decision marks a next chapter in an international career spanning more than three decades in pharma and biotechnology; Sturge most recently served at Merck as its Executive Vice President Global Strategy, Business Development & Global Operations.

Protecting public health: Is real-world evidence the key?

Published on 08/04/19 at 01:49pm

In often tough regulatory climates and with threats to public health are growing in sceptical corners of society, the need to deliver treatments and preventative therapies is a key concern for industry and national healthcare bodies. Matt Fellows explores how incorporating wider use of real-world evidence into these systems could be the solution we need.

Top Ten most popular articles on this week!

As Brexit looms, pharma trade lobby the ABPI called for a ban on exports of medicines in the case of no-deal Brexit. The industry organisation warned that a plummeting pound could incentivise distributors to sell drugs in markets abroad.

Meanwhile, this month’s feature ‘How I learned to stop worrying and love the placebo effect’ looked at what placebos mean for clinical trials. In talking to Harvard professor Dr Ted Kaptchuk, Louis Goss asked what the placebo effect is and what it means.

Crescendo Biologics selects current CFO Theodora Harold as new CEO

Published on: 04/04/19

Cambridge, UK-based Crescendo Biologics have said current Chief Financial Officer (CFO) Theodora Harold will take over from Dr Peter Pack as the company’s new CEO.

Cambridge University graduate Harold will succeed Dr Pack at the beginning of next month, after he steps down from his current position on 1 May 2019.

Sorrento Therapeutics seek $1 billion from billionaire biotech investor Patrick Soon-Shiong

Image Credit: NHS Confederation

Sorrento Therapeutics is seeking $1 billion in damages from billionaire biotech investor Patrick Soon-Shiong, owner of US newspaper the LA Times.  

The legal action comes after Sorrento accused Soon-Shiong of “catching and killing” a generic version of a cancer drug, which would have acted as competition to one owned by Celgene, a company in which he was the largest shareholder.

Sorrento claim Soon-Shiong acquired Cynviloq, a generic version of Celgene’s Abraxane, with the intention of stopping its progression to market.

Artios Pharma name experienced oncologist as company's new CMO

Published on: 01/04/19

British biotech Artios Pharma have appointed experienced oncologist Dr Ian Smith, as the company’s new Chief Medical Officer (CMO).

Dr Smith will join the Cambridge-based firm – which is focused on DNA Damage Response (DDR) as a treatment for cancer – as he takes responsibility for Artios’s overall preclinical and clinical development strategy, as well as the firm’s regulatory and medical activities.

Having graduated with a degree in medicine in 1992, Dr Smith brings more than 16 years of pharmaceutical industry experience to Artios.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches